Valuation: BioCardia Inc

Market Cap 10.98M 9.63M 8.89M 8.22M 15.57M 1.05B 15.88M 107M 41.53M 514M 41.23M 40.33M 1.79B P/E 2026 *
-1.42x
P/E 2027 * -1.84x
Enterprise Value 10.98M 9.63M 8.89M 8.22M 15.57M 1.05B 15.88M 107M 41.53M 514M 41.23M 40.33M 1.79B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
77%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/01/2002
Director of Finance/CFO 62 01/03/2016
Chief Tech/Sci/R&D Officer - 01/08/2017
Director TitleAgeSince
Chairman 90 01/01/2002
Director/Board Member 72 01/01/2011
Director/Board Member 62 02/12/2025
Date Insider Type Main position Quantity % Market Cap.
06/07Free

Director

8,000 0.0703%
06/07Free

Chief Executive Officer

57,688 0.5072%
06/07Free

Director

8,000 0.0703%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-3.68%+70.92%+126.05% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+1.49%+6.38%+23.06%+481.96% 25.26B
+0.45%-3.32%-15.63%-12.22% 23.65B
+3.93%+3.35%+43.09%-2.47% 18.69B
+1.63%+2.96%+40.69%-24.48% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-0.92%+1.58%+35.79% - 14.26B
+1.47%+2.44%+29.83%+200.03% 14.1B
Average +0.81%+4.02%+57.30%+154.13% 26.6B
Weighted average by Cap. +0.16%+2.20%+58.22%+143.84%

Financials

2026 *2027 *
Net sales - -
Net income -9.07M -7.96M -7.35M -6.79M -12.87M -869M -13.12M -88.31M -34.31M -425M -34.07M -33.32M -1.48B -10.02M -8.78M -8.11M -7.49M -14.2M -959M -14.49M -97.49M -37.88M -469M -37.61M -36.79M -1.63B
Net Debt - -
Logo BioCardia Inc
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-